Le Lézard
Classified in: Health
Subject: AWD

Bardy Diagnosticstm Selected as One of Six Disruptive MedTech Startups For the HealthTech Arkansas Accelerator Program


SEATTLE, Aug. 9, 2019 /PRNewswire/ -- Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in the organization's 2019 accelerator program. BardyDx was chosen for its innovative advancements in cardiac monitoring by delivering industry-leading diagnostic accuracy with the Carnation Ambulatory Monitor ("CAMtm"), the industry's only P-wave centrictm ambulatory cardiac patch monitor and arrhythmia detection device.

HealthTech Arkansas 2019 Cohort Announcement Reception, including BardyDx Chief Commercial Officer Ken Nelson (3rd from left), Arkansas Governor Asa Hutchinson (5th from left), and Director of HealthTech Arkansas Jeff Stinson (6th from left).

HealthTech Arkansas is a new and expanded iteration of two previous accelerator programs in the state, Health InnovatAR and HubX-LifeSciences. This year, with more provider partners and increased investment for participating companies, HealthTech Arkansas is focused on bringing the most innovative healthcare technologies to Arkansas. The 2019 cohort selection was announced this week at the Arkansas Heart Hospital with a welcome from CEO Dr. Bruce Murphy, followed by a message from Arkansas Governor Asa Hutchinson and presentations from each of the six chosen companies. Both Dr. Murphy and Governor Hutchinson focused on the importance of working together to bring innovative technologies to Arkansas.

"It's an honor to be selected as part of the 2019 accelerator cohort," said Ken Nelson, BardyDx Chief Commercial Officer. "HealthTech Arkansas presents an invaluable opportunity to perform clinical studies with highly-engaged and pioneering healthcare organizations that are eager to implement the newest innovative technologies, like the CAM patch, to advance their clinical care ? a clear win for both BardyDx and each partnering institution."

This year's six companies were selected from hundreds of applicants across 18 different countries. The cohort will participate in a program that provides them the opportunity to partner with and build solutions specifically identified by Arkansas Heart Hospital, Arkansas Children's, Arkansas Urology, Baptist Health, CHI St. Vincent, Conway Regional, Mercy, the University of Arkansas for Medical Sciences (UAMS), and Washington Regional Medical Center as areas of opportunity within their organizations. Each of the cohort companies will receive seed investment as well as complete and total access to clinicians and administrators at each partnering site.

"We're delighted to have the participation of BardyDx as one of six companies in our cohort this year," said Jeff Stinson, Director of HealthTech Arkansas. "Collectively, they're among the most accomplished early stage healthcare companies in the country. BardyDx was specifically chosen because the leadership teams in our partner hospitals believe the company can significantly increase the quality of care through its innovative devices. We can't wait to begin our work with BardyDx."

This distinction adds to the growing market recognition of the innovative P-wave centric CAM patch. Recently, BardyDx was named both the winner of the 2019 MedTech Breakthrough Award for Best New Diagnostic Technology and the winner of the 2019 Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring. Also, BardyDx was recently named the winner of the Impact Pediatric Health Competition hosted by the nation's leading pediatric healthcare institutions at SXSW 2019 for the CAM's unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was also selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.

About HealthTech Arkansas:

HealthTech Arkansas is a healthcare accelerator and investment fund that connects early stage healthcare companies bringing disruptive technologies to the market with Arkansas healthcare providers for the purpose of conducting pilot projects. We target the intersection of technology and healthcare in three categories: digital health (software), connected medical devices and diagnostic platforms. Our program is by providers and for providers, so we seek technologies that can improve our providers' quality of care and increase their efficiency. Additional information can be found at www.healthtecharkansas.com.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch monitors to the industry. The company's CAM patch is a non-invasive, P-wave centrictm ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling form factor. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis and the determination of appropriate medical or procedural intervention. For more information, please visit www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
[email protected]

BardyDx Carnation Ambulatory Monitor (CAMtm) - P-wave centrictm ambulatory cardiac patch monitoring and arrhythmia detection (PRNewsfoto/Bardy Diagnostics, Inc.)

We're close to your heart(TM)

SOURCE Bardy Diagnostics, Inc.


These press releases may also interest you

at 16:54
Hondros College of Nursing (HCN) will introduce a new Medical Assisting program at its six Ohio campuses in 2024 to meet the growing need for medical assistants in a variety of settings.  According to the U.S. Bureau of Labor Statistics (BLS),...

at 16:45
Halozyme Therapeutics, Inc. ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and...

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will...

at 16:35
Tilray Brands, Inc. , a leader in the craft beer and cannabis-lifestyle industries, celebrates high honors and awards at the 2024 Craft Brewer's Conference and World Beer Cup. 10 Barrel Brewing won four craft beer awards and 10...

at 16:34
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular...

at 16:30
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible...



News published on and distributed by: